



Response plan to *pfhrp2* gene deletions



Global **Malaria** Programme

Response plan to *pfhrp2* gene deletions



World Health
Organization

Table of contents



Acknowledgements	v
1. Introduction and objectives	1
2. Defining the issue	2
2.1 RDTs in malaria control	2
2.2 How RDTs work	4
2.3 Quality assurance	6
2.4 Evolution of <i>pfhrp2/3</i> deletion mutants	6
3. Response to the diagnostic threat	9
3.1 Pragmatic action by national malaria programmes	9
3.2 Strengthened laboratory networks	16
3.3 New research	21
3.4 Diagnostics research and development	23
3.5 Coordination of response	25
4. Conclusions	27
5. References	28

TABLES

Table 1.	Plasmodium antigens targeted by antibodies used in malaria RDTs	5
Table 2.	WHO Malaria RDT Product Testing: Rounds 5-8: Performance of RDTs not based exclusively on HRP2 for the detection of low density HRP2-expressing and non-expressing <i>P. falciparum</i> malaria	15
Table 3.	Causes of false-negative RDT results and investigative actions	17
Table 4.	Estimated numbers of samples from patients with falciparum malaria to be screened for false-negative HRP2 RDT results and numbers with suspected <i>prhrp2</i> deletion mutations, requiring molecular analysis, in all countries in which these mutations have been reported and in neighbouring malaria-endemic countries	19

FIGURES

Figure 1.	Data from manufacturers and national malaria control programmes on the volume and types of RDTs delivered worldwide, 2010–2017	3
Figure 2.	Immunological reaction on a positive RDT strip (example: <i>P. vivax</i> infection)	4
Figure 3.	Highest percentage of <i>pfhrp2</i> deletions reported amongst <i>P. falciparum</i> cases tested	7
Figure 4.	Projected malaria RDT demand by product type (2017–2021)	25

BOXES

Box 1.	Quality assurance for malaria RDTs	2
Box 2.	Standardized protocol for assessing national prevalence of <i>pfhrp2/3</i> deletion mutants among patients with falciparum malaria	4
Box 3.	Factors affecting the performance of pf-LDH combination RDTs against <i>pfhrp2/3</i> deleted parasites	14

ACKNOWLEDGEMENTS

We wish to acknowledge the contributions of Dr Mark Perkins, who drafted the document, Ms Rebecca Thomson and members of the Malaria Policy Advisory Committee (MPAC) whose inputs informed the final version. On behalf of the WHO Global Malaria Programme, the publication of the *Response plan to pfhrp2 gene deletions* was coordinated by Jane Cunningham with significant contributions from Andrea Bosman.

Funding for the production of this report was gratefully received from the Bill & Melinda Gates Foundation.



1. INTRODUCTION AND OBJECTIVES

Accurate, timely diagnosis of malaria is critical to case management and is a key element in national and global malaria control and strategies for elimination. Malaria microscopy, the traditional diagnostic approach, is difficult to implement in the decentralized settings where most malaria occurs; therefore, the advent of disposable lateral-flow immunoassays for malaria (widely known as rapid diagnostic tests, RDTs), has been of fundamental importance in modern malaria management, for targeting therapy, reducing drug wastage, and limiting pressure towards the development of resistance. Malaria RDTs are available from many manufacturers in various conformations. Ensuring the safety and quality of the RDTs used in malaria control and case management has been a major focus of WHO and its partners.

The clinically relevant RDTs for malaria diagnosis detect parasite proteins circulating in the blood. Some are configured to detect only *Plasmodium falciparum* and others, other *Plasmodium* species. The tests that are most sensitive in diagnosing falciparum malaria contain antibodies to detect the histidine-rich protein 2 (HRP2) and/or the related HRP3 protein. These protein targets, which are specific to *P. falciparum*, are strongly expressed by asexual parasites and have multiple copies of the target epitopes per protein. Some 10 years ago, researchers working in the Peruvian Amazon region identified patients infected with *P. falciparum* strains that had acquired deletions in the genes that encode these proteins (*pfhrp2* and *pfhrp3*), rendering them undetectable by HRP2-based RDTs. Since then, many studies have demonstrated the presence of such mutated strains in other countries and regions. The frequency and global distribution of this phenomenon is not yet fully understood, but, in a limited number of countries, the relative incidence of these deletion mutants has been found to be high enough to threaten the usefulness of HRP2-only RDTs.

This response plan to mutations that limit the effectiveness of HRP2-based RDTs comprises a framework intended to support national malaria control programmes and their implementing partners to address this problem pragmatically. The document also summarizes current knowledge and critical gaps in knowledge to guide future research and product development. The four objectives of an implemented response plan are to:

1. define the frequency and distribution of these diagnostically relevant mutations in circulating *P. falciparum* strains;
2. provide concrete guidance to countries on malaria diagnosis and treatment in settings where such mutations are found to be frequent;
3. identify gaps in knowledge about the genesis and spread of strains with *pfhrp2* and/or *pfhrp3* deletions and the actions required to develop new, accurate tests for malaria based on alternative target antigens; and
4. coordinate advocacy and communication with donors, policy-makers, test developers, research agencies, technical partners and disease control programmes to assist in planning.



2. DEFINING THE ISSUE

2.1 RDTs in malaria control

Malaria remains a huge global health risk, causing an estimated 219 million cases of febrile disease (range, 203–262 million) and 435 000 deaths in 2017. The greatest burden of malarial disease is in sub-Saharan Africa, responsible for approximately 90% of all malaria cases and malaria deaths (1). Nevertheless, impressive progress has recently been made in the control of malaria worldwide: between 2000 and 2015 alone, the incidence of malaria cases was reduced by 41% (2). Recent studies demonstrate that, even in African countries with endemic malaria, the great majority of cases of febrile illness are not due to malaria (3).

Malaria does not usually present with distinct physical signs that would allow accurate clinical diagnosis; and, as the incidence of malaria drops, confirmatory testing before treatment becomes essential. Timely, accurate diagnostic testing is the cornerstone of modern malaria control, and, since 2010, WHO treatment guidelines have included the recommendation that all cases of suspected malaria be tested by microscopy or an RDT (4). The benefits of diagnostic testing extend beyond malaria case management. As stated in the WHO *Global technical strategy for malaria 2016–2030* (5), “Expansion of diagnostic testing will provide timely and accurate surveillance data based on confirmed rather than suspected cases. Additionally, it will lead to improved identification and management of the many non-malarial febrile illnesses presumed to be malaria solely on the basis of the presence of fever.”

As malaria microscopy is not always feasible in primary care settings, the development of malaria RDTs based on lateral flow has been critical to current strategies for malaria control. Indeed, RDTs for malaria are one of the most successful diagnostic products in global health. With a disposable cassette to detect parasite antigens in finger-stick blood samples, they offer simple, unambiguous detection of malarial infection, allowing disease confirmation before treatment at primary care level. First developed in the early 1990s, malaria RDTs were initially little used, despite published reports of good performance (6). By 2002, nearly 10 million tests were being produced each year by about 24 manufacturers. In view of variations in manufacture and in published results, WHO and partners began a quality-assurance programme to ensure procurement of high-quality tests (**Box 1**). Once quality assurance was in place, donors and policy-makers were confident in extending use of RDTs for confirmatory testing.

BOX 1.

QUALITY ASSURANCE FOR MALARIA RDTs

Variation in the manufacture of RDTs, between both companies and manufacturing lots, can significantly affect their performance. In view of the large number of RDTs commercially available and the relative weakness of many national regulatory systems, WHO, the Foundation for Innovative New Diagnostics (FIND), the United States Centers for Disease Control and Prevention and other partners instituted a quality assurance programme, which has been functioning since 2008. The programme has three main elements: product testing to verify their performance against a standardized panel of blood samples, lot testing to ensure that each procured lot has maintained its specified criteria before distribution, and job-aids and training materials for health workers and trainers to support proper use.

Between 2007–2017, all companies that manufactured malaria RDTs in conformity with ISO13485:2003 were invited to submit RDTs for testing against a large bank of geographically diverse clinical specimens and cultured parasites to determine




their performance in detecting 200 or 2000 parasites/ μ L. The WHO malaria RDT product testing programme established performance parameters (e.g. sensitivity, specificity, stability, ease of use) and evaluated 297 new or newly submitted products. For a decade, the results of product testing formed the basis of the procurement criteria of WHO, other United Nations agencies, the Global Fund to Fight AIDS, Tuberculosis and Malaria, national governments and nongovernmental organizations. The results have shifted markets towards better-performing tests and are resulting in overall improvement in their quality. From 1 January 2018, WHO requires WHO prequalification for all *P. falciparum*-only HRP2 based RDTs and this requirement is expected to be progressively extended to all other products. WHO prequalification is dependent on attainment of performance criteria, successful dossier review and inspection of the manufacturing site.

Similarly, between 2007–2017, WHO and FIND supported two lot-testing sites, at the Research Institute for Tropical Medicine in the Philippines and the Pasteur Institute of Cambodia, to evaluate procured lots before their distribution for use to ensure that each lot was not degraded and that its performance is that determined during product testing. Capacity to meet national lot testing needs was also developed at the ANDI Centre of Excellence for Malaria Diagnosis, University of Lagos and the National Institute for Malaria Research, India. WHO is exploring opportunities to support partially decentralized lot testing in national reference laboratories through the use of reproducible and stable quality control materials, previously unavailable.

As shown in **Fig. 1**, RDT manufacture and sales exceeded 300 million tests per year by 2013 and 2014. The differences between the data from manufacturers and that from national malaria control programmes (NMCPs) as illustrated in Fig. 1 are probably due to the inclusion of sales in the private sector in the information supplied by manufacturers and incomplete reporting by some NMCPs. Use in Africa accounts for the vast majority of NMCP deliveries, and, as seen from the manufacturers' data, *P. falciparum*-only tests based on HRP2 detection predominate.

FIG. 1.
Data from manufacturers and national malaria control programmes on the volume and types of RDTs delivered worldwide, 2010–2017



Source: World Malaria Report 2018 (1)

The advent of RDTs and their widespread use, spurred by WHO policy and now adopted in the public sector by all 91 countries with continuous malaria transmission, has massively increased the fraction of all suspected cases of malaria that are confirmed prior to treatment. Such diagnostic certainty has averted millions of cases of mistreatment and overtreatment, has helped thousands of clinicians working in malaria-prone areas to understand that fever does not necessarily signify malaria, and has provided much clearer understanding of the current epidemiology of malaria during the drive towards its elimination. Access to such testing has improved: by 2015 some 80% of all malaria suspects attending public health facilities worldwide underwent confirmatory testing rather than a syndromic diagnosis (2).


The rates of diagnostic testing vary by geographical area, however, and are lowest for febrile children in Africa.

2.2 How RDTs work

RDTs are lateral-flow immunoassays that allow visualization of specific antigen-antibody recognition events. In routine use, a specified amount of fingerstick blood is transferred to one end of the RDT, the sample pad, which is loaded with reagents that lyse the blood cells to release any malaria antigens present and allow binding of monoclonal antibodies labelled with colloidal gold or another visible colorimetric indicator. Addition of a liquid buffer helps the blood wick up through the nitrocellulose membrane towards an absorbent pad. On the way, it crosses one or more test lines on the strip, where immobilized monoclonal antibodies can bind to exposed epitopes on *Plasmodium* proteins (*P. vivax* in **Fig. 2**) (7). In addition to test lines, which darken when malarial proteins are bound and detected, there is also a control line, which ensures that the sample pad reagents were liquified and wicked appropriately up the RDT membrane. As each test may have a slightly different configuration and require different handling (e.g. amount of buffer to be added, time until results), the instructions accompanying the tests must be followed closely.

FIG. 2.

Immunological reaction on a positive RDT strip (example: *P. vivax* infection)



Source: New perspectives: malaria diagnosis. Report of a joint WHO/USAID informal consultation, 25–27 October 1999 (7)



TABLE 1.
***Plasmodium* antigens targeted by antibodies used in malaria RDTs**

TARGET ANTIGEN	FULL ANTIGEN NAME	SELECTIVITY OF ASSAY	CHARACTERISTICS
HRP2	Histidine-rich protein II	Detects only <i>P. falciparum</i>	Water-soluble protein of unclear function that is abundantly produced by trophozoites and young gametocytes and contains repeating epitopes. Persists in serum for days to weeks after successful treatment.
Pf-LDH	<i>P. falciparum</i> parasite lactate dehydrogenase	Detects only <i>P. falciparum</i>	Soluble glycolytic enzyme produced by trophozoites and gametocytes. Blood levels decline rapidly during therapy.
Pv-LDH	<i>P. vivax</i> parasite lactate dehydrogenase	Detects only <i>P. vivax</i>	
Pvom-pLDH	Parasite lactate dehydrogenase from <i>P. vivax</i> , <i>P. ovale</i> , and <i>P. malariae</i>	Detects <i>P. vivax</i> , <i>P. ovale</i> and <i>P. malariae</i>	Key enzyme in the glycolysis pathway, with relatively conserved amino acid sequences. Relatively rapid clearance after therapy.
Pan-LDH	<i>Plasmodium</i> parasite lactate dehydrogenase	Detects all <i>Plasmodium</i> spp. that infect humans	
Aldolase	<i>Plasmodium</i> aldolase	Detects all <i>Plasmodium</i> spp. that infect humans	

Because of the wide prevalence and medical importance of falciparum malaria, essentially all RDTs contain antibodies that detect *P. falciparum* proteins (pan-pLDH, Pf-pLDH or HRP2). A number of factors are usually taken into account in selecting an antigen.

- Tests for HRP2 are often more sensitive than pLDH assays, in terms of both detecting smaller concentrations of protein and the clinical limit of detection (measured as parasites per microlitre) (11).
- HRP2 RDTs tend to be more heat stable.
- pLDH assays more accurately identify acute infection, as the target pLDH enzyme concentration falls quickly following parasite clearance with treatment, whereas HRPs may persist for weeks after treatment.
- Aldolase assays tend to be the least sensitive of the current RDTs.

The sensitivity of a given RDT depends on several factors, including the accuracy of testing procedures, the antigen concentration and other characteristics of the blood sample, the age and storage conditions of the test and the specificities of its manufacture, such as the selection of capture and detection antibodies, type of nitrocellulose, label and buffer conditions. False-negative result may be due to low parasite density (10), incorrect interpretation of results, gene deletion of the parasite target protein (e.g. *pfhrp2*) or a prozone effect (12).

2.3 Quality assurance

Almost 90% of suspected cases of malaria presenting for care in the public sector facilities in Africa are tested and RDTs accounted for 63% of malaria testing in 2016 (2). In 2014, procurement of malaria RDTs represented an investment of US\$ 103 million by multilateral and bilateral donors (13). Anything that compromises the utility of malaria testing or the accuracy of test procurement of malaria RDTs currently threatens the investment of US\$ 151 million annually by multilateral and bilateral agencies and the benefits of testing. RDTs that perform poorly have been excluded from the public market by dint of a large quality-control programme for RDT products before (by comparative testing of marketed products) and as part of procurement, by pre-shipment or post-shipment lot-testing (see **Box 1**). Recently, some RDT products have met the requirements of WHO prequalification (https://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/). Proper clinical testing with RDTs, including storage, training, procedural correctness, accuracy of recording results and adherence to results remain a concern in many settings.

2.4 Evolution of *pfhrp2/3* deletion mutants

In 2010, researchers who were characterizing malarial blood samples from the Amazon basin in Peru as part of the WHO product testing programme found that HRP2 was not detectable in the blood of some patients with *P. falciparum* infections that had been confirmed by microscopy (14). Molecular testing by polymerase chain reaction (PCR) and gene sequencing confirmed that the genes that encode this protein (and sometimes those that encode the structural homologue HRP3) were deleted from the parasite. These genetic deletions led to false-negative results in RDTs that target this protein, raising the spectre that, if the anomaly occurred in other countries, many infections with *P. falciparum* might remain undiagnosed and untreated. Subsequent analyses at other sites in the Loreto region of the Peruvian Amazon (15) showed a significant increase in the frequency of parasites with gene deletions in specimens collected in 1998–2001 (20.7%) and those collected in 2003–2005 (40.6%) (14, 16).

In a global survey of HRP2 sequence variation in 458 samples collected in 2008–2009 in 38 countries within the WHO RDT evaluation programme (17), substantial diversity was found in *pfhrp2/3* sequences, including the number and type of repeating epitopes, but no samples with *pfhrp2/3* deletions were found. Sequence variation did not substantially alter the sensitivity of RDTs to detect parasitaemia at a clinically important level (> 200 parasites/ μ L).


In a more recent, continuing global survey (<http://www.malariagen.net/projects/parasite/pdf>), *pfhrp2* and *pfhrp3* exons from 2671 blood samples collected from patients with *P. falciparum* infection were sequenced in the MalariaGEN *P. falciparum* Community Project, which is building a catalogue of variants and allele frequencies in order to characterize common genetic variations in *P. falciparum*. Samples from symptomatic and asymptomatic patients in 27 countries were contributed to the project by 32 investigators. Strong evidence of deletions of *pfhrp2* were found in 0.6% of all samples and identified in nine of the 27 countries. The frequency of *pfhrp2* deletions in collected samples was > 5% in those from only three countries – Indonesia (Papua Province), Kenya and Peru. Deletions of *pfhrp3* were more common, with an overall frequency of 2.4%, and were identified in 15 countries, in four of which > 5% of samples contained *pfhrp3* deletions. Mutations of both *pfhrp2* and *pfhrp3* were found in 0.3% of samples from six countries, and dual mutations were found in more than 5% of samples only from Kenya and Peru.¹

1. Unpublished data presented at a WHO technical consultation on *pfhrp2/3* gene deletions. Geneva; 7–8 July 2016.



A recent review of published reports found 51 studies from 36 journal publications, presenting data from 29 countries, which confirm that *P. falciparum* malaria strains with mutations that affect production of HRP2 and/or HRP3 proteins (hereafter called *pfhrp2/3* deletion mutants) have appeared in many regions endemic for malaria, in some cases at a prevalence that would significantly reduce the effectiveness of RDTs that test for this antigen to detect falciparum malaria (18). **Figure 3** shows the geographical distribution of reported *pfhrp2*-deleted parasites. The colour for each country represents the highest percentage of samples reported to have *pfhrp2* deletions, among all sites where studies were conducted in each country. Parasites that fail to express pLDH or aldolase antigens, which are enzymes critical for parasite survival, have not been reported.

FIG. 3.
Highest percentage of *pfhrp2* deletions reported among *P. falciparum* cases tested



Source: Thomson R, Parr, J, Perkins, M, Bosman A, Cheng Q, Cunningham J. Escaping detection: a systematic review of the study quality, prevalence and geographical distribution of *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3. Submitted for publication. (18)

Because of the large methodological differences between studies, especially in the selection of participants, only broad conclusions can be drawn.

1. There are clear local “hot spots” where *pfhrp2/3* deletion mutants are common enough to make diagnostic testing based only on HRP2 inadequate. Specifically, relatively high rates of *pfhrp2/3* deletions were seen in the Amazonian regions of Colombia (19) and Peru (14, 15, 20) and in Eritrea (21, 22) (**Figure 3**).
2. The prevalence of *P. falciparum* that do not express HRP2 varies by province in any given country. From 0–25% in India (23), 0–53.6% in Colombia (24) and 0–21.7% in the Democratic Republic of Congo (25). Similarly, although the presence of *pfhrp2/3* deletion mutants in a neighbouring country is a risk factor, it does not guarantee local circulation of such strains.
3. *pfhrp2/3* deletion mutants can cause epidemics, especially in low-transmission regions, which may be missed by HRP-based RDTs (20).

4. In many studies, the methods by which patients were selected resulted in overestimates of the true prevalence of *pfhrp2/3* deletion mutants. In Rwanda, for example, 32% of *P. falciparum* strains assessed by *pfhrp2* PCR were deletion mutants, but the only samples assessed were positive for falciparum malaria by microscopy and PCR and negative in HRP2 RDTs (26). If none of the HRP2-positive RDT results were due to *pfhrp2* deletion mutants, the true prevalence of *pfhrp2* deletions in microscopy-positive falciparum cases would be around 1%.
5. The data illustrated in Figure 3 may, however, underestimate the prevalence of *pfhrp2*-deleted strains because of cross-reactivity of HRP2-based RDTs with HRP3. As well, in areas of moderate-to-high transmission, the circulation of strains with *pfhrp2* deletions may be masked by coinfection with *P. falciparum* strains without such deletions, and infection with more than one strain type are common in these settings.
6. The absence of PCR amplification of *pfhrp2/3* may be due to an inadequate quantity of parasite DNA. In many studies, the DNA extraction and purification methods used did not provide enough amplifiable DNA to detect single-copy genes like *pfhrp2/3*.

WHO has begun tracking and reporting surveys of *pfhrp2/3* deletions using an online mapping tool, Malaria Threat Maps (<http://apps.who.int/malaria/maps/threats/>) (27). To aid interpretation of the results, the maps allow for results to be filtered based on the enrolment population (symptomatic vs. asymptomatic) and by single or double deletions of *pfhrp2* and *pfhrp3*. The Malaria Threat Map data is not independently assessed for quality of the studies performed; however, a recent systematic review provides a laboratory comprehensiveness indicator score on the basis of the clinical and molecular testing information available in the published report. This scoring was adapted from recommendations for standardization of testing and reporting of *pfhrp2/3* deletion mutations from Cheng et al. (28). Studies are assigned a score of 1 to 7 based on evidence of the following criteria (1 point each for:)

1. evidence of performance of quality assured microscopy (use of an HRP2 RDT for diagnosis that met WHO performance criteria (pg. 13));
2. evidence of quantitation of parasitaemia by microscopy or PCR;
3. testing for availability of amplifiable DNA using >1 single-copy *P. falciparum* genes;
4. evidence of molecular species identification;
5. testing for both HRP2 and HRP3 deletion;
6. use of another quality HRP2-based RDT, ELISA, or bead-based assay to confirm PCR findings.

The fulfillment of each criterion is given a score of 1, and the study score is the sum of all criteria scores. Overall, the findings suggest there is much room for improvement as only three publications (6%) met all the published criteria (28) And another nine publications (18%) fulfilled six out of seven criteria.

3. RESPONSE TO THE DIAGNOSTIC THREAT

There is now clear evidence from many countries of the emergence of *P. falciparum* strains that cannot be detected with the most common diagnostic tool used in primary care across Africa and beyond. The *Response plan to pfhrp2 gene deletions* proposes a multi-faceted response to this threat, which will require:

- pragmatic action by NMCPs and their implementing partners;
- strengthened laboratory networks;
- research to further understand the factors behind the development of these resistant strains and the global scope of the problem;
- research and development of improved RDTs; and
- a coordinated response by donors and policy-makers to avoid interruption in malaria diagnostic services.

3.1 Pragmatic action by national malaria programmes

The evolution and circulation of *pfhrp2/3* deletion mutants will threaten malaria control, like drug resistance, and must be managed. Although there are unanswered questions about the genesis and spread of HRP2/3-negative strains, NMCPs can act now, while further information is being collected. The programme management of *pfhrp2/3* deletion mutants described below includes guidance covered in the WHO information note on false-negative results in RDTs, published in May 2016 and updated in September 2017 and June 2019 (29).

In many areas traditionally endemic for malaria, the prevalence has fallen, and most of the RDTs used in testing febrile individuals give correctly negative results. Large studies conducted to follow the outcomes of febrile children for whom RDT results were *negative* (30, 31) found that it was safe not to treat them for malaria, with no malaria-related deaths or hospitalizations. That being said, in areas where *pfhrp2/3* deletions are found to be prevalent, as in Eritrea and Peru, NMCPs should switch to RDTs that do not rely exclusively on HRP2 for detecting *P. falciparum*. Circulation of *pfhrp2/3* deletion mutants is likely to be focal, and the introduction of a new testing strategy may be prioritized for regions or provinces with the highest prevalence of these mutants. Data from the prevalence survey recommended below will provide guidance to national programmes on changing their testing methods and the provinces or regions in which to apply the changes first.

WHO convened a meeting of experts to prepare guidance on *pfhrp2/3* mutations in July 2016 and published the outcome as a background document for the 2016 Malaria Policy Advisory Committee meeting (32). The group decided that a 5% local prevalence of false-negative HRP2 RDTs due to gene deletions would warrant a change in testing strategy. This cut-off was selected because it is at about that level that public health gains will be obtained in changing HRP2 detecting RDTs with those targeting pLDH antigens. At this threshold the proportion of cases missed by less sensitive non-HRP2-based tests are likely to be lower than those associated with continued use of HRP2-based tests. Future modelling based on rigorously collected programme data may be useful to confirm or refine this cut-off value. Based on few studies where repeat surveys were done over time, it is expected that strains carrying *pfhrp2/3* deletion mutations will continue to expand and spread, especially in areas where HRP2 testing predominates to guide treatment. All countries should therefore consider planning a



gradual transition to testing that does not rely solely on the detection of HRP2, and in the interim NMCPs should be prepared to investigate suspected deletions, introduce surveillance for *pfhrp2/3* deletions and act on the outcomes. Approaches are proposed below.

3.1.1. Investigating suspected false-negative RDTs for deletion mutants

The NMCPs and implementing partners in countries in which HRP2-based RDTs are used should support investigation of suspected false-negative RDT results for possible *pfhrp2/3* deletion mutants, considering the common causes of false-negative results, including operator error, false-positive microscopy results, degradation of RDTs during transport or storage, manufacturing error or infections with a low parasite density. *pfhrp2/3* gene deletions should be suspected and the NMCP and WHO informed when:

- a patient's sample gives a negative result on the HRP2 test line of at least two quality-assured malaria RDTs, a positive result on the pan or Pf-LDH line if a combination RDT is used and confirmation of positivity for *P. falciparum* by two qualified microscopists; or
- the rates of discordance between RDT and microscopy results in the programme are systematically ≥ 10 –15%, with higher positivity rates with microscopy, and quality is controlled routinely by cross-checking or both tests are performed for the same individuals (e.g. during a survey); and/or
- the NMCP and/or the manufacturer receives many formal complaints or anecdotal evidence that HRP-based RDTs are giving false-negative results for *P. falciparum*.

3.1.2. National assessment of the prevalence of *pfhrp2/3* deletion mutants

The interpretation of the survey data collected to date (See **Fig. 3**) is limited by methodological differences in the studies performed, particularly in the selection of patients or screening methods, resulting in large variations in the estimated prevalence of *pfhrp2/3* deletion mutants. When an NMCP or other credible group detects *pfhrp2/3* gene deletions in local strains, it should determine the prevalence in the country and in neighbouring countries in order to plan an appropriate response. Although the infrastructure of activities such as malaria indicator surveys and therapeutic efficacy studies may be used to determine the distribution of these strains, it is highly recommended that a standardized enrolment protocol be used in all countries so that the results will be comparable. WHO has published a protocol on its website (<http://apps.who.int/iris/bitstream/handle/10665/260140/WHO-CDS-GMP-2018.03-eng.pdf>) (33), which targets the most relevant group for case management and disease control: symptomatic individuals attending health facilities being evaluated for clinical malaria. The goal of the protocol, the elements of which are described below, is to determine rapidly whether the prevalence of *pfhrp2/3* deletion mutants causing false-negative RDT results among patients with falciparum malaria is high enough ($\geq 5\%$) to consider changing the malaria diagnostic strategy and tools. Clinical sites for enrolment of patients in surveys of the prevalence of *pfhrp2/3* deletion should be selected such that they represent the population distribution and the heterogeneity of transmission.

NMCPs may wish to establish sentinel sites to repeat estimates of the prevalence of *pfhrp2/3* deletions over time in order to determine whether changes in diagnostic testing are effective in controlling the transmission of deletion mutants. New initiatives to find these gene deletions are not currently recommended if there are no confirmed reports of *pfhrp2/hrp3* gene deletions locally or in neighbouring countries.



BOX 2.

STANDARDIZED PROTOCOL FOR ASSESSING NATIONAL PREVALENCE OF PFHRP2/3 DELETION MUTANTS AMONG PATIENTS WITH FALCIPARUM MALARIA

Subjects: Symptomatic patients with suspected falciparum malaria among those seen at minimum 10 health facilities per selected province.

Screening method: A high-quality RDT for detecting HRP2, preferably the same one being used by the NMCP and either microscopy or a second RDT for detecting Pf-pLDH. **Table 2** indicates which Pf-LDH RDTs can be used for survey purposes.

Selection criteria: All falciparum patients with uncomplicated malaria, for whom a suspected false-negative HRP2 RDT was found and who agree to participate.

Study method: Collect, label and dry a minimum of two finger-prick blood spots for molecular analysis. Conduct PCR testing of a dried blood spot for (i) species confirmation, (ii) level of parasitaemia, (iii) amplifiable DNA and (iv) the presence of genes that encode HRP2 and HRP3.

Sample size: 370 falciparum cases per province or region will be screened with dual RDTs or a HRP2-RDT and microscopy. Molecular analysis will then be undertaken on the samples suspected to have *pfhrp2/3* deletions and a statistical analysis of the prevalence with 95% CI will be computed. The analysis will result in one of three outcomes per province:

Outcome 1: That the upper limit of the 95% CI does not overlap with 5%. In this case there is a high statistical confidence that *pfhrp2/3* deletion causing false negative RDT results is below 5%.

Outcome 2: The lower limit of the 95% CI is above 5%. This result means that there is a high statistical confidence that *pfhrp2/3* deletion causing false negative RDT results is greater than 5%.

Outcome 3: The statistical analysis shows that it is inconclusive (5% contained within the 95% CI) as to whether or not the prevalence of *pfhrp2/3* deletion causing false negative RDT results is greater than or less than 5%.

Testing location: RDT and/or microscopy testing will be performed at local health facilities, with appropriate quality control. Molecular analysis may be performed at regional or international reference laboratories who perform *P. falciparum* PCR to a high standard and have experience in *pfhrp2/3* genotyping.

3.1.3. Response to survey outcome: >5% *pfhrp2* deletions causing false negative RDTs

If a survey confirms the presence of *pfhrp2/3* deletions causing false negative HRP2-RDTs is greater than 5% then the NMCP will need to take a series of actions to immediately optimize case management and plan for the introduction of replacement RDTs. Any change should be applied nationwide, although roll-out might be prioritized on the basis of the prevalence of *pfhrp2* deletions.

Step 1: Immediately introduce safeguards to reduce the impact of false negative RDTs results

A number of safeguards can be introduced and the choice and scope of implementation will be influenced by the prevalence and distribution of malaria and *pfhrp2* deletions causing false negative HRP2 RDTs, patient access to good quality microscopy, ACT stocks, the capacity to rapidly inform end-users and the feasibility of RDT product retrieval.

In the highest risk areas, initiate an order for health workers to immediately adopt alternative diagnostic algorithms depending on the type of HRP2 RDT being used (a, b, c, d):

a) HRP2-only RDT

- treat all positive cases as per national guidelines;
- send RDT negative patients for quality-assured microscopy; or
- if microscopy is not available or patient unlikely to follow through with referral, provide presumptive treatment.

b) HRP2/pan-LDH RDT

- treat all HRP2 and/or pan-LDH test line positive cases with ACTs to cover both HRP2 expressing and non-expressing *P. falciparum* and non-*P. falciparum* infections.

To confirm species, send pan-LDH test line-only positive cases, for quality-assured microscopy or perform a *P. vivax*-specific RDT.

c) HRP2/Pv-LDH RDT

- treat positive RDT results as per national guidelines;
- send RDT negative patients for quality-assured microscopy; or
- if microscopy is not available or patient unlikely to follow through with referral, provide presumptive treatment.

To avoid undermining confidence in RDTs, it is important that the communication accompanying the new diagnostic algorithm explains that RDT failures were most likely attributable to parasite factors and not due to the RDT defects.

In the case that prevalence of *pfhrp2* deletions causing negative RDT results is extremely high, as was the case in Eritrea (22), and confidence in RDT results has been severely eroded then the following algorithm should be considered:

d) Stop using HRP2-based RDTs and

- confirm diagnosis by quality-assured microscopy.



Where quality-assured microscopy services are not available or not accessible, treat all malaria suspects presumptively with ACTs.

Step 2: Investigate feasibility and resources for product retrieval

This decision will be based on the available resources, the interim diagnostic algorithm selected, the expiry dates of lots in the field and anticipated time before product replacement is deployed.

Step 3: Supplementary distribution +/- procurement of ACT stocks

If a decision is made to fully or partially introduce presumptive treatment of malaria suspects until replacement RDTs are distributed, the demand for ACTs will increase and will have to be matched with existing or supplementary stocks.

Step 4: Selection and procurement of replacement RDT

Ideally, all replacement RDTs being considered for use should either be WHO prequalified² or be in the WHO prequalification assessment pipeline³ and meet WHO performance criteria⁴ for detection of all *P. falciparum* strains, including those with *pfhrp2/3* deletions.

Until recently, the laboratory evaluation component of the prequalification process did not include *pfhrp2/3* deleted parasites and therefore performance against HRP2-expressing *P. falciparum* panels was assumed to be representative of test performance against non-HRP2-expressing parasites. However, Table 2 illustrates that this does not seem to be the case and the majority of pf-LDH targeting RDTs have poorer performance against the evaluation panel of *pfhrp2/3*-single and double deleted samples. Only pan-LDH-only RDTs maintained a high performance level against both HRP2 expressing and non-expressing *P. falciparum* panels. No combination test currently meets WHO *P. falciparum* panel detection score criteria **on both** HRP2-expressing and non-expressing panels. Given these challenging circumstances, interim guidance on procurement in areas with high prevalence of *pfhrp2* deletions is given here: https://www.who.int/malaria/publications/atoz/rdt_selection_criteria/en/ and will be updated as new data emerges and as RDTs of a new generation are developed and approved for general international procurement.

Table 2 lists the names and performance characteristics of RDTs evaluated in the WHO malaria RDT product testing programme (rounds 5–8) for the specific diagnosis of *P. falciparum* malaria by detection of non-HRP2 antigens, namely pan (all species)-LDH or Pf-LDH. Where available, performance data against a low parasite density panel of *pfhrp2/3* single and double deleted parasites is presented. Further details can be found in the report of round 8 of product testing (10). A green colour code indicates that RDTs meet WHO performance criteria. Results are presented separately for performance against *hrp2* expressing and *hrp2* negative panels. Only RDTs that are shaded green in both columns A and E in **Table 2**, should be used for clinical case management in areas where *pfhrp2* deletions are prevalent. Additionally, performance against *pfhrp2/3* negative samples with antigen concentrations reflecting 2000p/μL are included to inform selection of RDTs for use in surveys, as a *pfhrp2* deletion screening tool, based on the WHO survey protocol template (33). More specifically, only those RDTs that have a panel detection score of >90% against 2000 p/μL should be used to screen for suspected *pfhrp2* deletions.⁵

2 http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/

3 http://www.who.int/diagnostics_laboratory/pq_status/en/

4 panel detection score, ≥ 75% at 200 parasites/μL ; false-positivity rate, < 10% and invalid rate < 5%

5 RDTs should also have false positive and invalid rates < 2% (33)

a) RDT replacement for case management in areas with *pfhrp2* deletions and predominantly *P. falciparum* transmission

In summary, two pan-LDH-only RDTs meet WHO procurement criteria on both HRP2 expressing and non-expressing performance panels and would therefore be the top choice for RDT replacement in places where discriminating between *Plasmodium spp* is not a high priority ie. most of sub-Saharan Africa.

b) RDT replacement for case management in areas with *pfhrp2* deletions and mixed *P. falciparum* and non-*falciparum* transmission

Given that currently no pf-LDH containing combination RDTs meet performance criteria, a pan-LDH-only RDT is also the preferred option for deployment in these areas provided all RDT positive patients are treated with ACTs. *P. vivax* infection could only be confirmed by microscopy or by performing a second pv-LDH-specific RDT. The latter is required if *P. vivax* is treated with chloroquine and/ or if primaquine is administered for radical cure and also to maintain accuracy of routine reporting of *P. falciparum* vs. *P. vivax* infections.

Pf-LDH RDTs, with or without an HRP2 test line, will miss lower density infections (<2000 parasites/ μ L) caused by *pfhrp2/3* single or double deleted parasites, resulting in a false-negative for *P. falciparum* infection. Combination pf-LDH/ pan-LDH RDTs will result in a false-positive for non-*falciparum* infection when they are detected only on the pan-LDH test line.

Table 2 illustrates that there are several pf-LDH based combination RDTs that do perform well at higher densities/antigen concentrations. Ultimately, the impact of using these less sensitive pf-LDH test lines for clinical case management of *P. falciparum* in areas with *pfhrp2* deletions will be dependent on the interplay of various factors listed below (**Box 3**); however, most programmes will not have the required data to assess the impact of using less sensitive pf-LDH combination RDTs.

BOX 3.

FACTORS AFFECTING THE PERFORMANCE OF PF-LDH COMBINATION RDTs AGAINST *PFHRP2/3* DELETED PARASITES

- i) prevalence of *pfhrp2* deleted parasites in the population
- ii) HRP3 cross reactivity with HRP2 RDTs
- iii) the multiplicity of infection in the population – infections that include both HRP2 expressing and non-expressing *P. falciparum* isolates
- ii) prevalence of lower density infections – reviews suggest that between 0–30 % of symptomatic *P. falciparum* cases are < 200 parasites/ μ L (34).

When better performing RDTs using pf-LDH or other non-HRP2 antigens become available, another important consideration in selecting a replacement combination test will be the technical complexity. Although the protocol ie. blood volume, drops of buffer, reading time, for various RDT products is similar and unlikely to pose major difficulties for health workers, the test interpretation does vary considerably depending on the test line number, order and target antigen. Pilot testing some of these different options amongst a small group of intended users could provide valuable insight for product selection.

TABLE 2.

WHO Malaria RDT Product Testing: Rounds 5-8: Performance of RDTs not based exclusively on HRP2 for the detection of low density HRP2-expressing and non-expressing *P. falciparum* malaria (10)

Product	Manufacturer	<i>P. falciparum</i> HRP2 expressing, <i>P. vivax</i> and malaria negative panels				<i>P. falciparum</i> HRP2 non-expressing panel				Round	
		PDS ^a A ^b	B ^c	FP C ^d	IR D ^e	Meets WHO procurement criteria ^h	E ^f	PDS PF @ 2000p/ μ L	Meets WHO procurement criteria for detection of <i>pfhrp2/3</i> deleted <i>P. falciparum</i> ^m		Applicable for use with a HRP2 RDT, as screening tool for surveys of <i>pfhrp2</i> deletions ⁿ
Pf only											
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-line RDT ^r	Access Bio Inc.	82 (81/40) ¹	NA	0.5	0.0	No	12.5 (0/12.5)	100	No	Yes	8
CareStart™ Malaria Pf (HRP2/pLDH) Ag RDT	Access Bio Ethiopia	88.0	NA	0.0	0.0	No	17.5	100	No	No	8
CareStart™ Malaria Pf (HRP2/pLDH) Ag RDT	Access Bio Inc.	96.0	NA	0.0	0.0	Yes ^g	60.0	100	No	No	8
careUS™ Malaria Combo Pf (HRP2/pLDH) Ag	WELLS BIO, INC	89.0	NA	0.0	0.0	No	22.5	100	No	No	8
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) ^r	Standard Diagnostics Inc. (Alere)	90 (88/77)	NA	0.0	0.1	Yes ^g	32.5 (0/32.5)	100	No	Yes	8
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines	Standard Diagnostics, Inc.	90.0	NA	0.0	0.1 (231)	No	UK	UK	UK	No	7
EzDx Malaria Pf Rapid malaria Antigen detection test (pLDH)	Advy Chemical Pvt. Ltd.	10.0	NA	5.8	0.0	No	12.5	100	No	Yes	8
Pf and Pan											
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT	Access Bio Inc.	83.0	97.1	1.0	0.1	No	0.0	82.5	No	No	8
CareStart™ Malaria Screen RDT	Access Bio, Inc.	93.0	94.3	0.0	0.1 (231)	No	UK	UK	UK	UK	7
Malaria pf (pLDH) / PAN-pLDH Test Device	AZOG, Inc.	41.0	8.6	81.3 (235)	0.1	No	UK	UK	UK	UK	5
MERISCREEN Malaria pLDH Ag	Meril Diagnostics Pvt. Ltd.	27.0	100.0	1.0	0.0	No	10.0	100	No	Yes	8
Pf and Pv/Pvom											
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH)	RapiGEN Inc.	75.0	100.0	0.0	0.6 (230)	Yes	UK	UK	UK	Yes	7
Pf, Pf and Pv											
SD BIOLINE Malaria Ag Pf/Pf/Pv ^r	Standard Diagnostics Inc. (Alere)	89 (89/62)	97.1	0.0	0.0	Yes ^g	20 (0/20)	100	No	Yes	8
Pan only											
Advantage Pan Malaria Card	J. Mitra & Co. Pvt. Ltd.	77.0	100.0	0.4	0.0	Yes			UK	No	5
CareStart™ Malaria PAN (pLDH) Ag RDT	Access Bio, Inc.	84.0	88.6	0.0	0.0	Yes ^g	100 ^k	100 ^l	Yes	No	5 ^{kl}
CareStart™ Malaria PAN (pLDH) Ag RDT	Access Bio Ethiopia	98.0	97.1	9.1	0.0	Yes	90.0		Yes	No	8
careUS™ Malaria PAN (pLDH) Ag	WELLS BIO, INC	98.0	85.7	5.3	0.0	Yes	85.0		Yes	No	8



Abbreviations: UK: unknown; Pf: *Plasmodium falciparum*; Pv: *Plasmodium vivax*; pan: *Plasmodium species*; Pvom: *Plasmodium vivax, ovale and malariae*

Performance criteria (highlighted in green if met):

- A: *P. falciparum* panel detection score (PDS) \geq 75% at 200 parasites/ μ L
 - B: *P. vivax* panel detection score (PDS) \geq 75% at 200 parasites/ μ L
 - C: false-positive (FP) rate against clean negatives < 10%
 - D: invalid rate (IR) < 5%
 - E: *pfhrp2* negative *P. falciparum* panel detection score (PDS) > 75% at 200 parasites/ μ L (in areas where *pfhrp2* deletions are prevalent)
- a A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive
 - b Round 1, n=79; Round 2, n=100; Round 3, n=99; Round 4, n=98; Round 5, n=100; Round 6, n=100; Round 7, n=100; Round 8, n=100
 - c Round 1, n=20; Round 2, n=40; Round 3, n=35; Round 4, n=34; Round 5, n=35; Round 6, n=35; Round 7, n=35; Round 8, n=35
 - d Round 1, n=168; Round 2, n=200; Round 3, n=200; Round 4, n=232; Round 5, n=236; Round 6, n=208; Round 7, n=220; Round 8, n=208
 - e Round 1, n=954; Round 2, n=1240; Round 3, n=1204; Round 4, n=1192; Round 5, n=1214; Round 6, n=1210; Round 7, n=1210; Round 8, n=1210
 - f PDS presented in the table is based on a positive Pf test line (either HRP2 or Pf-LDH). The results in brackets are the PDS based alone on HRP2 and Pf-LDH test lines, respectively.
 - g Indicates a WHO prequalified product (as 15 February 2019), see updates at: https://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report/en/
 - h <https://www.who.int/malaria/news/2019/rdt-procurement-criteria/en/>
 - i Round 8, n=40 (18 double deletion: *pfhrp2*-/*pfhrp3* -; 22 single deletion; *pfhrp2*-/*pfhrp3*+))
 - j Results (PDS) of adhoc assessment of *pfLDH* containing round 8 RDTs against high density HRP2 negative panel : n=40 (18 double deletion: *pfhrp2*-/*pfhrp3* -; 22 single deletion; *pfhrp2*-/*pfhrp3*+))
 - k Results (PDS) of adhoc assessment of this product against the round 8 low density HRP2 negative panel n=40 (18 low density double deletion: *pfhrp2*-/*pfhrp3* -; 22 single deletion; *pfhrp2*-/*pfhrp3*+))
 - l Results (PDS) of adhoc assessment of this product against a high density HRP2 negative panel n=40 (18 low density double deletion: *pfhrp2*-/*pfhrp3* -; 22 single deletion; *pfhrp2*-/*pfhrp3*+))
 - m These results should be considered when procuring RDT for use in areas where *pfhrp2* + or - *pfhrp3* deletions are prevalent.
 - n RDTs including *pf*-LDH individual test lines that have a PDS >90% against *pfhrp2* deleted parasite samples of 2000 parasites/ μ L may be used to screen for *pfhrp2* deletions as per WHO survey protocol template (33)

Step 5: Re-training and roll out

While awaiting the arrival of the replacement RDT(s), plans should be developed for re-training and supervision including relevant adaptations of training materials, standard operating procedures, job aids etc. Routine report forms may also need to be revised to most accurately reflect the results of one or more new RDTs. The roll out of training and replacement RDTs should be prioritized from high to low prevalence of *pfhrp2/3* deletions causing false negative HRP2-RDTs. Coupling retraining in RDTs with refresher training in microscopy should be strongly considered in areas with both *P. falciparum* and non-*falciparum* species, and where programmes will be reliant on microscopy for species confirmation.

Ultimately, encouraging manufacturers to submit their products to WHO prequalification and evaluating currently prequalified products against a larger geographically diverse panel of clinical *pfhrp2/3* deleted isolates are top priorities. Longer term, the development of tests that can meet the full set of criteria should be actively pursued, and opportunities are discussed in section 3.5 below.

3.2 Strengthened laboratory networks

Strengthening laboratory capacity for the detection of malaria has been a critical feature of national and international malaria control. The emergence and expansion of *P. falciparum* strains that cannot be detected with HRP2-based RDTs will further stretch local laboratory capacity, both for microscopy and RDT testing. Although expert microscopy has repeatedly shown good performance, microscopy services in peripheral settings have been difficult to establish and maintain, and many reports document poor sensitivity and poor specificity in the field detection of malaria by microscopy (35–38). Meeting the requirement for capacity to assess suspected false-



negative HRP2-based RDTs will require quality-assured microscopy and/or staff trained and ready to use correctly non-HRP2-only RDTs that are not in routine use in the NMCP.

In addition to assessing individual reports of suspected false-negative RDT results, national surveys should be conducted to establish the prevalence of *pfhrp2/3* deletion mutants, which would require more training and perhaps staff recruitment, depending on local workloads. Survey protocols will also require procurement and distribution of Pf-pLDH-based RDTs. As each RDT has specific instructions for use, maintenance of multiple testing methods in 10 health facilities per province – at least during a survey for *pfhrp2/3* deletion mutants – will not be trivial.

Discordant test results between two different RDTs may be due to many factors, and not all HRP2-negative, Pf-pLDH-positive RDT results are due to *pfhrp2/3* deletions (see **Table 3** Causes of false-negative RDT results and investigative actions).

TABLE 3.
Causes of false-negative RDT results and investigative actions

CLASSIFICATION	CAUSE OF FALSE-NEGATIVE RDT RESULT	SUGGESTED ACTIONS
Operator factors	Operator error in preparing the RDT, performing the test or interpreting the result	Verify whether RDTs are used by untrained staff; assess RDT competence on site.
Use of an imperfect “gold standard” as a comparator	Thick or thin films from a patient with a negative RDT result are incorrectly interpreted as “positive” by microscopy.	Verify microscopy procedures and interpretation by a qualified microscopist.
Product design or quality	Poor sensitivity of an RDT due to poor specificity, affinity or insufficient quantity of antibodies. Poor packaging can result in exposure to humidity, which will rapidly degrade RDTs.	Inspect the instructions for errors; inspect the integrity of the packaging, including the colour indicator desiccant for evidence of moisture. Cross-check suspected false-negative RDT results against microscopy performed by two qualified microscopists or, if microscopy is not available, against a high-quality non-HRP2-detecting RDT; retrieve RDTs from affected areas and send for lot testing to WHO-recognized laboratories ^a .
	Poor visibility of test bands due to strong background colour on the test	Assess RDT performance and training on site; if the strong background colour persists, notify the manufacturer.
	Incorrect instructions for use	Review the instructions for use for accuracy.
Transport or storage conditions	Antibody degradation due to poor resistance to heat or incorrect transport or storage, e.g. exposure to high temperatures, freeze-thawing	Inspect temperature monitoring of RDT transport and storage chain to determine whether temperatures exceed maximum storage temperature, typically 30 °C or 40 °C or < 2 °C. If temperatures are not within those in the manufacturer’s instructions, send the RDTs to the WHO lot testing laboratory ^a . Train health workers to respect storage conditions, and improve storage places (e.g. add fans).

CLASSIFICATION	CAUSE OF FALSE-NEGATIVE RDT RESULT	SUGGESTED ACTIONS
Parasite factors	Parasites lack or express low levels of the target antigen, i.e. HRP2	Patient samples are negative on an HRP2 test line of at least two quality-assured malaria RDTs and positive on the pan- or pf-pLDH test line if a combination RDT is used and the sample is confirmed to be positive microscopically for <i>P. falciparum</i> by two qualified microscopists. If these conditions are met, place fresh blood samples or dried blood spots (50–60 µL) on Whatman® 3MM filter paper or other collection cards, in frozen storage (-20 °C) until shipment for PCR confirmation of <i>P. falciparum</i> and <i>pfhrp2/pfhrp3</i> gene analysis.
	Variation in the amino acid sequence of the epitope targeted by the monoclonal antibody	Repeat test with an RDT of a different brand or different manufacturer that targets the same antigen or an RDT that targets a different antigen, e.g. pan-pLDH or Pf-pLDH. Manufacturers may use monoclonal antibodies that target different epitopes of the same antigen.
Host parasite density	Very low parasite density or target antigen concentration	Perform high-quality microscopy and record the parasite count; if high-quality microscopy is not available, repeat the RDT if symptoms persist.
	Very high parasite load (severe malaria) causing prozone effect (hyperparasitaemia and antigen overload)	Repeat testing with a 10 × and if needed a subsequent 50 × dilution of the sample, with dilutions in 0.9% NaCl ^b

a Information about lot testing can be found here: <http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/evaluation-lot-testing/en/> (accessed: 26 June 2018)

b Gillet et al. Prozone in malaria rapid diagnostics tests: how many cases are missed? *Malar J* 2011; 10:166. <https://doi.org/10.1186/1475-2875-10-166>

In some settings, less than half of all suspected false-negative HRP2 RDTs are found to be due to *pfhrp2/3* deletions, while in others the predictive value of a false-negative HRP2 RDT for genetic deletion is much greater. Molecular analysis will be essential. Confirming the presence of genetic deletions will require sampling, labelling and preparation of dried blood spots for shipping and multiple PCR analyses in regional or international laboratories. This work should be done in a timely manner so that the NMCP can plan possible procurement of new types of RDT.

Table 4 shows estimates of the volume of conventional (RDTs and microscopy) and molecular testing required to perform surveys in all provinces of countries that have reported the presence of *pfhrp2/3* deletion mutants and in neighbouring countries. The numbers in the table are based on the assumption that malaria is transmitted in all provinces, which will not be true in many countries with areas of interrupted transmission. The goal of a national HRP2 survey is to determine whether the prevalence of *pfhrp2* deletions causing false negative RDTs in any province is $\geq 5\%$, the cut-off recommended for local use of non-HRP2-only diagnostics for falciparum malaria. The prevalence is calculated as the number of *pfhrp2/3* deletion mutants causing false-negative RDTs divided by the total number of cases of falciparum malaria.

TABLE 4.

Estimated numbers of samples from patients with falciparum malaria to be screened for false-negative HRP2 RDT results and numbers with suspected *prhrp2* deletion mutations, requiring molecular analysis, in all countries in which these mutations have been reported and in neighbouring malaria-endemic countries

COUNTRIES WITH <i>PFHRP2</i> DELETIONS REPORTED	NEIGHBOURING COUNTRIES	NUMBER OF ADMINISTRATIVE DIVISIONS	MINIMUM NUMBER OF FALCIPARUM CASES TO IDENTIFY	NUMBER OF MOLECULAR ASSESSMENTS AT 2% HRP RDT DISCORDANCE	NUMBER OF MOLECULAR ASSESSMENTS AT 5% HRP RDT DISCORDANCE	NUMBER OF MOLECULAR ASSESSMENTS AT 20% HRP RDT DISCORDANCE
South/ Central America						
Bolivia		9	3330	67	167	666
	Argentina	24	8880	178	444	1776
	Chile	15	5550	111	278	1110
	Paraguay	18	6660	133	333	1332
	Peru ^a	26	9620	192	481	1924
Brazil		27	9990	200	500	1998
	Uruguay	19	7030	141	352	1406
Colombia		33	12210	244	611	2442
	Ecuador ^a	24	8880	178	444	1776
	Panama	10	3700	74	185	740
	Venezuela	24	8880	178	444	1776
Suriname		10	3700	74	185	740
	French Guiana	24	8880	178	444	1776
	Guyana	10	3700	74	185	740
Guatemala		22	8140	163	407	1628
	Belize	6	2220	44	111	444
	El Salvador	14	5180	104	259	1036
	Honduras ^a	18	6660	133	333	1332
	Mexico	32	11840	137	592	2368
Nicaragua		17	6290	126	315	1258
	Costa Rica	7	2590	52	123	518
Africa/ Middle East						
DRC		29	10730	215	537	2146
	Angola	18	6660	133	333	1332
	Burundi	18	6660	133	333	1332
	Central African Republic	17	6290	126	315	1258
	Republic of Congo	12	4440	89	222	888
	Rwanda ^a	5	1850	37	93	370
	South Sudan	28	10360	207	518	2072
	Tanzania	31	11470	229	574	2294
	Uganda ^a	4	1480	30	74	296
Eritrea		6	2220	44	111	444
	Djibouti	6	2220	44	111	444
	Ethiopia ^a	9	3330	67	167	666
	Sudan	32	11840	237	592	2368



COUNTRIES WITH <i>PfPRP2</i> DELETIONS REPORTED	NEIGHBOURING COUNTRIES	NUMBER OF ADMINISTRATIVE DIVISIONS	MINIMUM NUMBER OF FALCIPARUM CASES TO IDENTIFY	NUMBER OF MOLECULAR ASSESSMENTS AT 2% HRP RDT DISCORDANCE	NUMBER OF MOLECULAR ASSESSMENTS AT 5% HRP RDT DISCORDANCE	NUMBER OF MOLECULAR ASSESSMENTS AT 20% HRP RDT DISCORDANCE
Ghana		10	3700	74	185	740
	Côte d'Ivoire	14	5180	104	259	1036
	Burkina Faso	13	4810	96	241	962
	Togo	5	1850	37	93	370
Kenya		47	17390	348	870	3478
	Somalia	18	6660	134	333	1332
Mali		9	3330	67	167	666
	Mauritania	15	5550	111	278	1110
	Algeria	48	17760	355	888	3552
	Niger	16	5920	118	296	1184
	Guinea	7	2590	52	130	518
Mozambique		11	4070	81	204	814
	Malawi	28	10360	207	518	2072
	South Africa	9	3330	67	167	666
	Zimbabwe	10	3700	74	185	740
	Kingdom of Eswatini ^a	4	1480	30	74	296
Senegal		14	5180	104	259	1036
	Gambia	9	3330	67	167	666
	Guinea-Bissau	8	2960	59	148	592
Yemen		22	8140	163	407	1628
	Saudi Arabia	13	4810	96	241	962
Zambia		10	3700	74	185	740
	Botswana	17	6290	126	315	1258
	Namibia	14	5180	104	259	1036
Asia						
India		36	13320	266	666	2664
	Bangladesh ^a	8	2960	59	148	592
	Bhutan	20	7400	148	370	1480
	Nepal	7	2590	52	130	518
	Pakistan	34	12580	252	629	2516
Myanmar		7	2590	52	130	518
	China	27	9990	200	500	1998
	Laos	18	6660	133	333	1332
	Thailand	77	28490	570	1425	5698
		1209	447330	8852	22373	89466

^a - *pfhrp2* deletions have been reported but neighbouring countries already listed and counted



Molecular analysis can be performed on dried blood spots, but the technical work is complex and requires PCR for species confirmation, quantification, extraction and recovery of sufficient undegraded *Plasmodium* DNA and analysis of the exons and flanking genes of *pfhrp2* and *pfhrp3*. As deletion mutations can be detected only as the absence of amplified products of *pfhrp* exons, rigorous control must be used to ensure the presence of non-degraded, amplifiable parasite DNA and lack of amplicon contamination. PCR to detect the absence of amplification can be confounded by multiple factors, including the specific reaction conditions, a concentration of target genetic sequences below the limit of detection, degradation of the target DNA, or presence of contaminating native or amplicon DNA. It is recommended that all samples from patients in the survey that are found to have a suspected false-negative HRP2 RDT be sent for molecular analysis. Thus, the number of samples to be analysed genetically will depend on prevalence of *pfhrp2/3* deletion mutants (and frequency of other events causing false-negative results). As illustrated in **Table 4**, if 20% of falciparum patients in HRP2 surveys are suspected of having false-negative HRP2 RDT results, the total number of samples that require molecular analysis would reach 89 466.

A number of international reference laboratories with experience in *pfhrp2/3* molecular analysis are already collaborating with WHO. Although these laboratories have shown willingness to contribute to better understanding of the causes and distribution of these mutated falciparum strains and to perform molecular testing of samples obtained in national HRP surveys, the manpower and the reagents for the predicted workload are not currently funded or guaranteed. National programmes themselves may have an interest in using or strengthening local capacity for PCR; however, the lack of PCR standardization and of a malaria molecular assay stringently approved by a regulatory authority will make comparison of results between studies and between laboratories problematic (39). The consequences of false-positive and false-negative results for *pfhrp2/3* gene deletions will have serious negative consequences. WHO is therefore committed to working with expert laboratories and donors to strengthen global capacity for detection of *pfhrp2/3* deletions. Where the capacity exists, regional and national laboratories with molecular expertise could play an important role, but it will be incumbent upon countries embarking on national HRP2 deletion surveys to have a molecular assessment plan that includes the capacity and agreements to ship samples internationally to collaborating laboratories with the necessary capacity and quality control. All laboratories that conduct malaria PCR are encouraged to participate in the WHO external quality assurance scheme for malaria nucleic acid amplification testing (<https://www.who.int/malaria/areas/diagnosis/nucleic-acid-amplification-tests/en/>), established in 2017 (40). Under this scheme, participants receive proficiency testing panels twice a year that include all *Plasmodium* species in a range of parasite densities.

3.3 New research

Although the precise physiological function of HRP2 and its structural analogue HRP3 is still unknown, much is known about the structure and variability of the genes that encode them. Both HRP2 and HRP3 are encoded by single-copy genes located in subtelomeric regions of chromosomes 8 and 13, respectively. These regions near the end of the chromosome are known to have multiple repeating elements and are hot spots for mutations, and these qualities are used by some parasites (e.g. *Trypanosoma brucei*) to generate variable surface antigens in order to escape the host immune system. *P. falciparum* strains containing intact *pfhrp2* genes often have variable gene sequences. In a study of 458 *P. falciparum* strains collected globally, 315 different *pfhrp2* gene sequences were found. Of the subset of 80 strains in which the *pfhrp3* gene was also sequenced, 42 different sequences were found (17). Although there is some evidence that such sequence variation can affect the clinical sensitivity of tests based on specific monoclonal antibodies, this is seen only near the limit of detection and has a limited effect on overall clinical sensitivity (except in the case of outright

gene deletion) (41). Deletion mutations that halt the expression of HRP2 or HRP3 may occur at various locations around the *pfhrp* exons and are frequently large, involving not only the relevant *pfhrp* genes but also upstream and downstream flanking genes.

There are no conclusive data on the transmissibility of *pfhrp2/3* deletion mutants as compared with that of wild-type parasites; however, they are clearly transmitted from person to person and may be responsible for epidemics that could be missed in areas in which HRP2-only RDTs are used. In 2010, an outbreak of 210 cases of genotypically identical falciparum malaria cases occurred in the Tumbes region of northern Peru, where autochthonous transmission had been stopped and which had been malaria-free for the previous 4 years (20). Genotyping of 188 *P. falciparum* strains with *pfhrp2* deletions collected over seven years in areas of Peru with ongoing transmission showed increasing clonal diversity, with clear evidence of the evolution of new strains carrying deletions (15).

The specific factors that drive the evolution and spread of *pfhrp* mutations are not clear, although it is sensible to consider that selective pressure due to HRP2 detection plays an important role; however, this is not the only factor. For example, in Peru, where HRP2-only RDTs were not used routinely, the prevalence of *pfhrp2* deletion mutants among cases in the area of Iquitos increased from 20.7% in samples collected between 1998 and 2001 to 40.6% among those collected between 2003 and 2005 (15). Data from a demographic and health survey in the Democratic Republic of the Congo indicate a link between a higher prevalence of *pfhrp2* deletions and earlier introduction of HRP2-based RDTs (25). Whether the strictness of adherence to diagnostic results in providing therapy helps drive the emergence of deletion mutants is unclear, although the predominance of these strains in Eritrea, where NMCP guidelines are followed closely, is noteworthy. In two recent studies, mathematical models were used to characterize the effect of introducing HRP2-based RDTs on the emergence and spread of *pfhrp2/3* deletion mutants (42, 43). These show that there is a high potential for *pfhrp2*-negative parasites to spread through a community when detection of *P. falciparum* malaria depends solely on PfHRP2. However, there is no conclusive empirical evidence that the choice of an RDT influences the prevalence of *pfhrp2/3* deletion mutants in a community, although such data may well emerge after widespread replacement of HRP2-only RDTs in Eritrea and their limited use in Peru.

Some clinical evidence suggests that *pfhrp*-deleted strains have reduced fitness. Cohorts infected with non-HRP2-expressing strains, which included young children, showed a lower parasite density than geographically matched cohorts infected with wild-type parasites (25). The results of studies with cultured parasites are inadequate to draw precise conclusions about the fitness of *pfhrp2/3* deletion mutants, although one study suggested that these strains showed reduced fitness in vitro (44).

In addition to research meant to understand the factors that drive the evolution and spread of *pfhrp2/3* deletion mutants, operational and technical research is needed to simplify the process of identifying and tracking the distribution of these strains. The currently proposed process for identifying these mutant strains is complex and requires some clinical trial infrastructure and sophisticated confirmatory testing. Surrogate markers that are easier to use are needed. For example, there is as yet no compiled information on the predictive value of a suspected false-negative HRP RDT for genetic mutations in different settings. Even if the predictive value were relatively low, if the difference between RDT and molecular results were fixed in given settings, that could serve as a useful marker to use to track trends. On a technical level as well, more research is needed. The current molecular methods require a substantial number of controls, as the readout is a negative one (deletion mutations are identified by the absence of a PCR result, which could be caused by many factors). A method that could detect mutations with a positive result would simplify molecular testing. Similarly, there may be simpler centralized testing methods that could provide results of adequate



accuracy for epidemiologic studies. A sensitive and quantitative method to measure the concentration of several proteins in multiplex might provide a cheaper and simpler reference method than molecular testing. Liquid array technologies, such as the Luminex platform, have already been used to create assays that detect HRP2 protein at sub-picogram levels and can be used for moderate to high-throughput testing (45). Optimization and multiplexing of such assays could provide a useful alternative to PCR to confirm RDT results.

3.4 Diagnostics research and development

The occurrence of strains that do not express HRP2/3 increases the likelihood that some infected patients will be missed in conventional RDT testing. The manufacture of RDTs and their components has been refined over the past 20 years, but there has been little change in *Plasmodium* protein targets. Many of the antigens evaluated in RDTs or enzyme-linked immunosorbent assays (ELISAs) were identified during research, including vaccine development, that was not intended to develop antigen immunocapture assays, and little work has focused on this area in recent years.

Glutamate dehydrogenase, a cytosolic protein of *P. falciparum*, was an early target for malaria antigen detection (46, 47) but was never used in a commercialized assay. Interest in the histidine-rich family of proteins of *P. falciparum* grew from the finding that HRP1 was an important protein in knob formation on erythrocytes, a virulence characteristic of *P. falciparum* (48). The finding that HRP2 was secreted, abundant and antigenic indicated its possible utility as a diagnostic target (49). HRP2 was first reported to be detectable (by ELISA) in the plasma of malaria patients in 1991 (50), and by 1993 a lateral flow immunochromatographic assay suitable for field use had been developed (6, 51).

Plasmodium LDH became an attractive target for malaria diagnostics when it was realized that the protein had both species-specific and pan-specific epitopes against which monoclonal antibodies could be developed. Furthermore, pLDH was found to be cleared from the blood much more rapidly than HRP2 after effective malaria treatment, rendering it a more specific target for the diagnosis of acute infection, especially in high-transmission areas (52).

Other plasmodium proteins, such as dihydrofolate reductase-thymidylate synthase, haem detoxification protein, glutamate-rich protein (53) and glyceraldehyde-3-phosphate dehydrogenase (54), have been studied for diagnostic potential but never used in a commercialized assay.

Although there has been abundant work on the proteomics of malaria, much of it has focused on understanding the fundamental biology of the organism, such as the events that mediate stage maturation of the parasites. Most studies have been done on cultures, and only some have been rigorously quantitative. A recent quantitative study of the proteins expressed in the intraerythrocytic *P. falciparum* parasites which are abundant, soluble and unlikely to be confused with human proteins, identified three that deserve further research as diagnostic targets: phosphoethanolamine *N*-methyltransferase, hypothetical protein PF11270w and a protein disulfide isomerase (55). Although proteins such as HRP2 are present in concentrations of nanograms to micrograms per millilitre, there have been virtually no quantitative proteomic studies of the comparative abundance of plasmodial proteins in human clinical samples.

An additional strategy that deserves exploration is use of existing reagents and targets in new assay configurations that have advantages in terms of sensitivity, quantification

and ease of use. Greater optimization of monoclonal antibodies or other ligands, to increase their robustness, thermostability and affinity (e.g. monoclonal antibodies with high binding affinity to both HRP2 and HRP3) would also be valuable.

In the short term, perhaps the most pressing need is non-HRP2 RDTs that target Pf-pLDH or another antigen target that are more sensitive and heat stable than the non-HRP2 tests currently available. In terms of analytical sensitivity, there is a roughly 10-fold gap between the detection capacity of HRP2 and pLDH assays. A more sensitive pLDH assay, especially one that targets Pf-pLDH, would have great benefits. Foremost, it would allow countries to phase out HRP2-based assays if *pfhrp2/3* deletion mutants reach important thresholds and replace them with assays of comparable performance. Secondly, countries that wish to track the prevalence of potential *pfhrp2/3* deletion mutants or to distinguish between new and recent infections could use assays with separate test lines for HRP2 and Pf-pLDH. Countries in which *P. falciparum* is prevalent and that wish to maintain testing and result recording that are as simple as possible could use tests with a single test band that bears both antigens, without fear of missing cases carrying deletion mutants or infections at low parasite density.

Unfortunately, RDT manufacturers are working within very tight profit margins. The market is so competitive and the tests so inexpensive that even critical quality control cannot always be funded. Manufacturers are therefore unlikely to fund even translatable research on reagent optimization and certainly not on the identification of improved biomarkers; external funding will be needed. Policy-makers and independent donors should consider innovative ways to fund science which is most urgently required to meet public health goals in the short term.

In May 2016, WHO announced that the companies that manufacture malaria RDTs must submit their products to be assessed in the WHO prequalification of in-vitro diagnostics programme. To date, the WHO prequalification programme, and the WHO-FIND RDT evaluation programme before it, have not included *pfhrp2/3* deletion mutants in the cultured or clinically collected reference specimens. This change is now being made to the product testing programme, and round 8 (laboratory evaluation for WHO prequalification) includes such specimens. Continuous dialogue among manufacturers, WHO and procurement agencies is necessary to ensure that NMCPs can procure in a timely manner products with performance that they can continue to rely upon.

3.4.1 Market size projections


In order for manufacturers to optimally plan R&D efforts and to respond efficiently to procurement needs, demand forecasts for alternative RDTs, that are not fully dependent on HRP2 for *P. falciparum* diagnosis, are needed. However, forecasts are challenging to generate when our understanding of the scope of *pfhrp2/3* deletion and the pace with which deletions will spread is unknown. Even when the intent to replace an RDT is made, policy change, product registration and procurement at national level introduce inevitable delays. Nonetheless, if one considers that approximately 49% of current public sector RDT use is in countries that have reported *pfhrp2/3* deletions and this increases to 85% when their neighbours are included (Table 4), it is plausible that demands for change could emerge quickly over the next 3–5 years.

In these “high risk” countries (i.e. where deletions have been reported and their neighbours), 61% (33 of 54) use HRP2-only *P. falciparum* tests which could be replaced immediately by pan-LDH only tests, so the demand is likely to increase first



for these RDTs. Approximately 23% of current global public sector RDT demand is for combination RDTs that detect and distinguish between *P. falciparum* and *non-falciparum* malaria. The countries reporting *pfhrp2/3* deletions and their neighbours comprise an estimated 82% of the combo-RDT market. While this market is smaller than the *P. falciparum*-only market, currently there are no RDTs on the market meeting WHO performance criteria for countries that cannot rely on HRP2 detection and that need to differentiate between species. Thus, the threat of *pfhrp2/3* deletions is most dire in these areas. Based on several assumptions, Figure 4 illustrates one scenario of how demand for tests for not relying exclusively on HRP2 may evolve over the period 2017–2021. This projection assumes that the market size remains relatively flat (56). It assumes that countries with reported deletions begin to shift their volumes to new tests at a faster rate than neighbouring countries.

FIG. 4.
Projected malaria RDT demand by product type (2017-2021)



Specifically, the projection assumes that in countries where deletions have been reported, 10%, 20%, 30% and 40% of RDT volumes in 2018, 2019, 2020, and 2021 respectively shift to tests that do not rely exclusively on HRP2 detection for *P. falciparum*. For neighbouring countries there is a one-year lag, i.e. 0%, 10%, 20%, and 30% of RDT volumes in 2018, 2019, 2020, and 2021 respectively shift to tests that do not rely exclusively on HRP2 detection for *P. falciparum*.

3.5 Coordination of response

There are many different interests involved in the discovery, development, quality control, selection, procurement, distribution, storage and use of RDTs. Without a coherent and coordinated response, there is a risk of inefficiency, delay, and missed opportunity to continue with the recent gains in malaria control. An effective response to this challenge will require specific work to coordinate the actions of the multiple agencies and governments involved. Given the strength and interest of partners, a small secretariat, perhaps hosted by WHO, could provide structure (communication, development of workplans, financing forecasts, etc.) to a time-limited collaboration or consortium intended to harvest the individual capabilities of partners and ensure harmonized action.

An example list of near term products and activities for the consortium might include:

- Market forecasting for commercial manufacturers
- Refinement and maintenance of the RDT quality assurance testing
- Registry of *pfhrp2/3* prevalence surveys

- Ongoing global mapping of data from prevalence surveys available through the WHO Malaria Threat Maps (27)
- Nominated and funded network of reference labs
- Annually updated policy reviews, especially around the prevalence cut-offs for changing RDTs in use and the recommendations on test selection
- Centralized procurement assistance for countries changing RDTs
- Short-term operational and technical research agendas with clear timelines and deliverables and financing needs
- Target product profiles published on ideal RDT configuration for now and 5 years from now

4. CONCLUSIONS

The emergence of *P. falciparum* strains that no longer express the HRPs that are the targets of the most commonly used malaria diagnostic tool globally is an extraordinary event, which threatens the utility of a critical weapon in the fight against malaria. The full extent of that threat is not yet known and the alternative RDT options i.e. Pf-pLDH RDTs are extremely limited and currently have inferior performance to HRP2 RDTs for *P. falciparum* detection. It is already a matter of urgent concern in the disparate regions of the Amazon basin and Eritrea, where the prevalence of false-negative HRP2 RDTs is forcing changes in diagnostic strategy. Information for much of the rest of the world is spotty, and the occurrence of these deletion mutants is known to be highly focal. It is likely that the problem will not go away and that, under continued selective pressure from testing and treatment strategies based on HRP2-only RDTs, it will continue to grow.

Managing the response will require needs-based prioritization – it would be counterproductive to attempt to change diagnostic test selection across Africa if unwarranted. National and global response must balance the risk of missed cases of falciparum malaria due to *pfhrp2/3* deleted strains against the equally real risk of missing cases by changing to a less sensitive RDT and the longer-term risk of eroding confidence in antigen-based confirmatory testing for malaria.

Several types of work are needed urgently:

- mapping the distribution and frequency of *pfhrp2/3* deletion mutants with harmonized protocols;
- building an international network of laboratories to perform the complex molecular confirmation required for mapping;
- supporting countries in the selection and procurement of new RDTs when a change of testing is warranted;
- advising commercial manufacturers of the priorities for new tests and providing the best available market forecasts;
- adapting the WHO malaria RDT product testing programme, which constitutes the laboratory evaluation component of WHO prequalification, to ensure proper validation of tests for the detection of *pfhrp2* deletion mutants as part of their intended use;
- working with donor agencies and research institutes to devise a funding plan to support (i) the interim costs for prevalence surveys and the necessary molecular testing and (ii) the search for improved diagnostic targets and high-affinity reagents; and
- strengthening coordination among policy-makers, NMCPs and their implementing partners, molecular testing laboratories, diagnostic industry representatives, donors and technical agencies to maximize efficiency in tracking and responding to this novel situation.

Achieving these goals within the time frame necessary to satisfy the needs of National Malaria Control Programs and the populations they serve will require a focused, staffed, and budgeted effort, and a mechanism for programme management.



5. REFERENCES

1. World malaria report 2018. Geneva: World Health Organization; 2018.
2. World malaria report 2016. Geneva: World Health Organization; 2016.
3. D'Acromont V, Lengeler C, Genton B. Reduction in the proportion of fevers associated with *Plasmodium falciparum* parasitaemia in Africa: a systematic review. *Malaria journal*. 2010;9:240. Epub 2010/08/24. doi: 10.1186/1475-2875-9-240. PubMed PMID: 20727214; PubMed Central PMCID: PMCPMC2936918.
4. Guidelines for the treatment of malaria. 2nd edition. Geneva: World Health Organization; 2010.
5. Global Technical Strategy for Malaria 2016–2030. Geneva: World Health Organization; 2015.
6. Dietze R PM, Boulos M, Luz F, Reller B and Corey GR. The diagnosis of *Plasmodium falciparum* infection using a new antigen detection system. *The American journal of tropical medicine and hygiene*. 1995;52:45-9.
7. New perspectives: malaria diagnosis. Report of a joint WHO/USAID informal consultation, 25–27 October 1999 (WHO/Mal 2000). Geneva: World Health Organization; 2000.
8. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). *The American journal of tropical medicine and hygiene*. 2007;77(6 Suppl):119-27. Epub 2008/01/31. PubMed PMID: 18165483.
9. Pacific WHOROfTW. A total list of ISO:13485 certified manufacturers and their RDT products. Manila.
10. Malaria rapid diagnostic test performance: Results of WHO product testing of malaria RDTs: round 8 (2016–2018). Geneva: World Health Organization; 2018.
11. Gatton ML, Rees-Channer RR, Glenn J, Barnwell JW, Cheng Q, Chiodini PL, et al. Pan-*Plasmodium* band sensitivity for *Plasmodium falciparum* detection in combination malaria rapid diagnostic tests and implications for clinical management. *Malaria journal*. 2015;14:115. Epub 2015/04/19. doi: 10.1186/s12936-015-0629-z. PubMed PMID: 25889624; PubMed Central PMCID: PMCPMC4371878.
12. Luchavez J, Baker J, Alcantara S, Belizario V, Jr., Cheng Q, McCarthy JS, et al. Laboratory demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests: implications for clinical management. *Malaria journal*. 2011;10:286. Epub 2011/10/01. doi: 10.1186/1475-2875-10-286. PubMed PMID: 21957869; PubMed Central PMCID: PMCPMC3214175.
13. World Health Organization (host organization for UNITAID). *Malaria Diagnostic Technology and Market Landscape*. 3rd Edition. 2016.
14. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PloS one*. 2010;5(1):e8091. doi: 10.1371/journal.pone.0008091. PubMed PMID: 20111602; PubMed Central PMCID: PMC2810332.



15. Akinyi S, Hayden T, Gamboa D, Torres K, Bendezu J, Abdallah JF, et al. Multiple genetic origins of histidine-rich protein 2 gene deletion in *Plasmodium falciparum* parasites from Peru. *Sci Rep.* 2013;3:2797. Epub 2013/10/01. doi: 10.1038/srep02797. PubMed PMID: 24077522; PubMed Central PMCID: PMC3786299.
16. Maltha J, Gamboa D, Bendezu J, Sanchez L, Cnops L, Gillet P, et al. Rapid diagnostic tests for malaria diagnosis in the Peruvian Amazon: impact of pfhrp2 gene deletions and cross-reactions. *PloS one.* 2012;7(8):e43094. Epub 2012/09/07. doi: 10.1371/journal.pone.0043094. PubMed PMID: 22952633; PubMed Central PMCID: PMC3429466.
17. Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of *Plasmodium falciparum*: implications for the performance of malaria rapid diagnostic tests. *Malaria journal.* 2010;9:129. Epub 2010/05/18. doi: 10.1186/1475-2875-9-129. PubMed PMID: 20470441; PubMed Central PMCID: PMC32893195.
18. Thomson R, Parr JB, Perkins M, Bosman A, Cheng Q, and Cunningham J. Escaping detection: a systematic review of the study quality, prevalence and geographical distribution of *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3. Submitted for publication 2019.
19. Solano CM, Okoth SA, Abdallah JF, Pava Z, Dorado E, Incardona S, et al. Deletion of *Plasmodium falciparum* Histidine-Rich Protein 2 (pfhrp2) and Histidine-Rich Protein 3 (pfhrp3) Genes in Colombian Parasites. *PloS one.* 2015;10(7). doi: 10.1371/journal.pone.0131576. PubMed PMID: WOS:000358158900020.
20. Baldeviano GC, Okoth SA, Arrospide N, Gonzalez RV, Sanchez JF, Macedo S, et al. Molecular Epidemiology of *Plasmodium falciparum* Malaria Outbreak, Tumbes, Peru, 2010–2012. *Emerging infectious diseases.* 2015;21(5):797–803. Epub 2015/04/22. doi: 10.3201/eid2105.141427. PubMed PMID: 25897626; PubMed Central PMCID: PMC34412223.
21. Menegon M, L'Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C. Identification of *Plasmodium falciparum* isolates lacking histidine-rich protein 2 and 3 in Eritrea. *Infect Genet Evol.* 2017;55:131–4. Epub 2017/09/12. doi: 10.1016/j.meegid.2017.09.004. PubMed PMID: 28889944.
22. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major Threat to Malaria Control Programs by *Plasmodium falciparum* Lacking Histidine-Rich Protein 2, Eritrea. *Emerging infectious diseases.* 2018;24(3):462–70. Epub 2018/02/21. doi: 10.3201/eid2403.171723. PubMed PMID: 29460730; PubMed Central PMCID: PMC5823352.
23. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of pfhrp2 and/or pfhrp3 Gene Deletion in *Plasmodium falciparum* Population in Eight Highly Endemic States in India. *PloS one.* 2016;11(8):e0157949. doi: 10.1371/journal.pone.0157949. PubMed PMID: 27518538; PubMed Central PMCID: PMC4982695.
24. Dorado EJ, Okoth SA, Montenegro LM, Diaz G, Barnwell JW, Udhayakumar V, et al. Genetic Characterisation of *Plasmodium falciparum* Isolates with Deletion of the pfhrp2 and/or pfhrp3 Genes in Colombia: The Amazon Region, a Challenge for Malaria Diagnosis and Control. *PloS one.* 2016;11(9). doi: 10.1371/journal.pone.0163137. PubMed PMID: WOS:000383723700037.

25. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrp2-Deleted *Plasmodium falciparum* Parasites in the Democratic Republic of the Congo: A National Cross-sectional Survey. *The Journal of infectious diseases*. 2017;216(1):36-44. doi: 10.1093/infdis/jiw538. PubMed PMID: 28177502.
26. Kozycki CT, Umulisa N, Rulisa S, Mwikarago EI, Musabyimana JP, Habimana JP, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact of *Plasmodium falciparum* isolates lacking hrp2 and declining malaria transmission. *Malaria journal*. 2017;16. doi: 10.1186/s12936-017-1768-1. PubMed PMID: WOS:000397733300003.
27. World Health Organization. Malaria Threat Maps. Available from: <http://apps.who.int/malaria/maps/threats/>.
28. Cheng Q, Gatton ML, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. *Malaria journal*. 2014;13:283. Epub 2014/07/24. doi: 10.1186/1475-2875-13-283. PubMed PMID: 25052298; PubMed Central PMCID: PMC4115471.
29. False-negative RDT results and implications of new reports of *P. falciparum* histidine-rich protein 2/3 gene deletions. Geneva: World Health Organization; 2017.
30. Senn N, Rarau P, Manong D, Salib M, Siba P, Robinson LJ, et al. Rapid diagnostic test-based management of malaria: an effectiveness study in Papua New Guinean infants with *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Clin Infect Dis*. 2012;54(5):644-51. Epub 2011/12/27. doi: 10.1093/cid/cir901. PubMed PMID: 22198787.
31. Baiden F, Webster J, Tivura M, Delimini R, Berko Y, Amenga-Etego S, et al. Accuracy of rapid tests for malaria and treatment outcomes for malaria and non-malaria cases among under-five children in rural Ghana. *PloS one*. 2012;7(4):e34073. Epub 2012/04/20. doi: 10.1371/journal.pone.0034073. PubMed PMID: 22514617; PubMed Central PMCID: PMC3325982.
32. World Health Organization. *P. falciparum* hrp2/3 gene deletions. Conclusions and recommendations of a Technical Consultation. Geneva, Switzerland, 7-8 July 2016. Background document for Session 7, Malaria Policy Advisory Committee Meeting, 14-16 September 2016, Geneva, Switzerland (WHO/HTM/GMP/MPAC/2016.12). Geneva: 2016.
33. World Health Organization. Protocol for estimating the prevalence of pfhrp2/pfhrp3 gene deletions among symptomatic falciparum patients with false-negative RDT results Geneva2018. Available from: <http://www.who.int/malaria/publications/atoz/hrp2-deletion-protocol/en/>.
34. Parasitological confirmation of malaria diagnosis: WHO technical consultation. Geneva, 6-8 Oct 2009. Geneva: World Health Organization; 2009.
35. Kahama-Maró J, D'Acremont V, Mtasiwa D, Genton B, Lengeler C. Low quality of routine microscopy for malaria at different levels of the health system in Dar es Salaam. *Malaria journal*. 2011;10:332. Epub 2011/11/04. doi: 10.1186/1475-2875-10-332. PubMed PMID: 22047131; PubMed Central PMCID: PMC3217957.
36. Mukadi P, Lejon V, Barbe B, Gillet P, Nyembo C, Lukuka A, et al. Performance of Microscopy for the Diagnosis of Malaria and Human African Trypanosomiasis by Diagnostic Laboratories in the Democratic Republic of the Congo: Results

of a Nation-Wide External Quality Assessment. *PloS one*. 2016;11(1):e0146450. Epub 2016/01/21. doi: 10.1371/journal.pone.0146450. PubMed PMID: 26788725; PubMed Central PMCID: PMCPMC4720473.

37. Stow NW, Torrens JK, Walker J. An assessment of the accuracy of clinical diagnosis, local microscopy and a rapid immunochromatographic card test in comparison with expert microscopy in the diagnosis of malaria in rural Kenya. *Trans R Soc Trop Med Hyg*. 1999;93(5):519–20. Epub 2000/03/04. PubMed PMID: 10696409.
38. McKenzie FE, Sirichaisinthop J, Miller RS, Gasser RA, Jr., Wongsrichanalai C. Dependence of malaria detection and species diagnosis by microscopy on parasite density. *The American journal of tropical medicine and hygiene*. 2003;69(4):372–6. Epub 2003/12/03. PubMed PMID: 14640495; PubMed Central PMCID: PMCPMC2504332.
39. Alemayehu S, Feghali KC, Cowden J, Komisar J, Ockenhouse CF, Kamau E. Comparative evaluation of published real-time PCR assays for the detection of malaria following MIQE guidelines. *Malaria journal*. 2013;12:277. Epub 2013/08/10. doi: 10.1186/1475-2875-12-277. PubMed PMID: 23927553; PubMed Central PMCID: PMCPMC3750446.
40. World Health Organization. *Nucleic acid amplification-based diagnostics*. Geneva: 2017.
41. Kumar N, Singh JP, Pande V, Mishra N, Srivastava B, Kapoor R, et al. Genetic variation in histidine rich proteins among Indian *Plasmodium falciparum* population: possible cause of variable sensitivity of malaria rapid diagnostic tests. *Malaria journal*. 2012;11:298. Epub 2012/08/30. doi: 10.1186/1475-2875-11-298. PubMed PMID: 22929537; PubMed Central PMCID: PMCPMC3475030.
42. Watson OJ, Slater HC, Verity R, Parr JB, Mwandagalirwa MK, Tshetu A, et al. Modelling the drivers of the spread of *Plasmodium falciparum* hrp2 gene deletions in sub-Saharan Africa. *Elife*. 2017;6. Epub 2017/08/25. doi: 10.7554/eLife.25008. PubMed PMID: 28837020; PubMed Central PMCID: PMCPMC5602420.
43. Gatton M DJ, Chaudhry A, Ciketic S, Cunningham J and Cheng Q. Implications of Parasites Lacking *Plasmodium falciparum* Histidine-Rich Protein 2 on Malaria Morbidity and Control When Rapid Diagnostic Tests are Used for Diagnosis. *Journal of Infectious Diseases*. 2017;215(7):1156–66.
44. Wellems TE WD, Smith CL, do Rosario VE, Maloy WL, Howard RJ, Carter R and McCutchan TF. A histidine-rich protein gene marks a linkage group favored strongly in a genetic cross of *Plasmodium falciparum*. *Cell*. 1987;49(5):633–42.
45. Rogier E PM, Lucchi N, Mace K, Chang M, Lemoine JF, Candrinho B, Colborn J, Dimbu R, Fortes F, Udhayakumar V and Barnwell J. Bead-based immunoassay allows sub-picogram detection of histidine-rich protein 2 from *Plasmodium falciparum* and estimates reliability of malaria rapid diagnostic tests *PloS one*. 2017.
46. Ling IT CS, Bates PA, Hempelmann E and Wilson RJM. Antibodies to the glutamate dehydrogenase of *Plasmodium falciparum*. *Parasitology*. 1986;92:313–24.
47. Li Y NY, Li L, Penh DD, Dong WQ and Li M. Preparation of a monoclonal antibodies against *Plasmodium falciparum* glutamate dehydrogenase and establishment of colloidal gold-immunochromatographic assay. *J Med Coll PLA*. 2005;25:435–8.



48. Kilejian A SY, Karoui H and Naslund L. Histidine-rich domain of the knob protein of the human malaria parasite *Plasmodium falciparum*. *Proc Natl Acad Sci U S A*. 1986;83:7938-41.
49. Howard RJ, Uni S, Aikawa M, Aley SB, Leech JH, Lew AM, et al. Secretion of a malarial histidine-rich protein (Pf HRP II) from *Plasmodium falciparum*-infected erythrocytes. *J Cell Biol*. 1986;103(4):1269-77. Epub 1986/10/01. PubMed PMID: 3533951; PubMed Central PMCID: PMCPMC2114335.
50. Parra ME, Evans CB, Taylor DW. Identification of *Plasmodium falciparum* histidine-rich protein 2 in the plasma of humans with malaria. *J Clin Microbiol*. 1991;29(8):1629-34. Epub 1991/08/01. PubMed PMID: 1761684; PubMed Central PMCID: PMCPMC270175.
51. Shiff CJ PZaMJ. The rapid manual ParaSight-F test. A new diagnostic tool for *Plasmodium falciparum* infection. *Trans R Soc Trop Med Hyg*. 1993;87:646-8.
52. Piper R LJ, Wentorth L, Hunt-Cooke A, Houze S, Chiodini P and Makler M. Immunocapture diagnostic assays for malaria using *Plasmodium lactate dehydrogenase* (pLDH). 1999;60:109-18.
53. Kattenberg JH, Versteeg I, Migchelsen SJ, Gonzalez IJ, Perkins MD, Mens PF, et al. New developments in malaria diagnostics: monoclonal antibodies against *Plasmodium dihydrofolate reductase-thymidylate synthase*, heme detoxification protein and glutamate rich protein. *MAbs*. 2012;4(1):120-6. Epub 2012/02/14. doi: 10.4161/mabs.4.1.18529. PubMed PMID: 22327435; PubMed Central PMCID: PMCPMC3338946.
54. Krause RGE, Hurdalay R, Choveaux D, Przyborski JM, Coetzer THT, Goldring JPD. *Plasmodium glyceraldehyde-3-phosphate dehydrogenase*: A potential malaria diagnostic target. *Exp Parasitol*. 2017;179:7-19. Epub 2017/05/30. doi: 10.1016/j.exppara.2017.05.007. PubMed PMID: 28552792.
55. Foth BJ, Zhang N, Chaal BK, Sze SK, Preiser PR, Bozdech Z. Quantitative time-course profiling of parasite and host cell proteins in the human malaria parasite *Plasmodium falciparum*. *Mol Cell Proteomics*. 2011;10(8):M110 006411. Epub 2011/05/12. doi: 10.1074/mcp.M110.006411. PubMed PMID: 21558492; PubMed Central PMCID: PMCPMC3149090.
56. Unitaid CHAI, IMS Health, Univeristy of California San Francisco. Global Malaria Diagnostic and Artemisinin Treatment Commodities Demand Forecast, 2017-2021. 2018.



For further information please contact:

Global Malaria Programme
World Health Organization

20, avenue Appia
CH-1211 Geneva 27

Switzerland

Email: infogmp@who.int